Home » Newsletters » BioWorld

BioWorld

July 27, 1999

View Archived Issues

Appointments And Advancements

Other News To Note

Maxim Raises $20M For Phase III Programs

FDA Declines To Approve Magainin's Antibiotic Drug

Neuron-Saving Ganglioside Drug Seeks 150 Parkinson Patients To Sign Up For Phase II Study

Targeted Genetics, Elan Team In Venture For Gene Delivery

NaPro, Abbott Partner In Deal Worth Up To $125M

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.